The Pharma week,distilled.

Viatris has agreed to acquire Pacira for $1.7 billion to expand its non-opioid pain treatment portfolio.

Ultragenyx Pharmaceutical has agreed to sell its Rare Pediatric Disease Priority Review Voucher, earned for the drug Genglycos, for $210 million.

The Canadian Weston family, through their holding company Wittington Investments, has agreed to acquire the UK pharmacy and beauty retailer Boots for $8.9 billion.

Google DeepMind, Meta, and Isomorphic Labs are investing $300 million into the Chan Zuckerberg Biohub to support the development of a 'virtual cell' for biological research.

The Canadian branch of the Weston family has agreed to acquire the UK pharmacy chain Boots for $8.9 billion, a figure that includes debt.

McKesson and private-equity firm Clayton, Dubilier & Rice have agreed to acquire home-infusion provider Option Care Health in a deal valuing the company at approximately $5.8 billion.

Private equity firm CD&R and healthcare conglomerate McKesson have announced an agreement to acquire infusion therapy provider Option Care Health for $5.8 billion.

Japanese pharmaceutical company Shionogi & Co. has announced the acquisition of biotech firm IntraBio for $2 billion.

Also: 06 Oct — genengnews.com

NHS England has launched a new digital service that sends prescription readiness alerts directly to patients' smartwatches and mobile devices.

The US FDA has approved Merck's Lipfendra, the first oral PCSK9 inhibitor designed to lower LDL cholesterol.

Amazon has transitioned its healthcare strategy from simple distribution to an integrated model using AI and cloud technology.

On October 7, 2026, the AI communications company Infinitus announced the launch of FieldForce, a suite of agentic AI tools designed for pharmaceutical sales representatives and field reimbursement managers.

On October 5, 2026, Utah regulators announced a new pilot program allowing the startup Nolla Health to use AI to evaluate patients for acne treatment and issue prescriptions.

Costco reported a 20% growth in pharmacy sales during its fourth-quarter earnings call, driven by the expansion of its GLP-1 drug programs and digital services.

Lycia Therapeutics is planning an initial public offering (IPO) to raise capital for the development of its next-generation protein degrader therapies.

Caribou Biosciences, a Berkeley, California-based biotech company, announced on October 6, 2026, that it is discontinuing its two remaining therapeutic programs, vispacabtagene regedleucel (vispa-cel) and CB-011.

The Royal College of Pharmacy has terminated its sponsorship and exhibition agreement with Teva UK, the British subsidiary of Teva Pharmaceuticals, following pressure from pro-Palestine activists.

The Pharmaceutical Research and Manufacturers of America (PhRMA) filed a lawsuit on October 7, 2026, in the U.S. District Court for the District of Columbia against the Trump administration.

The American Hospital Association, the Maine Hospital Association, and three community-based providers filed a lawsuit against the U.S. Department of Health and Human Services (HHS) and the Health Resources and Services Administration (HRSA) in the U.S. District Court for the District of Maine.

Research presented at an aging conference in Boston indicates that GLP-1 weight-loss drugs, manufactured by Eli Lilly and Novo Nordisk, may reduce biological age by two to three years in overweight and diabetic patients.

The National Institutes of Health (N.I.H.) is launching a new initiative in December 2026 to accelerate the development of cancer vaccines.

Henri Kagan and Kensō Soai were awarded the 2026 Nobel Prize in Chemistry for their research on chemical asymmetry and homochirality.

At the ESC Congress 2026, GLP-1 receptor agonists received their first formal heart failure guideline recommendation.

Cerevance, a spinout from Takeda, has completed Phase 3 clinical trials for its Parkinson's disease drug candidate, solengepras.

Henri Kagan and Kenso Soai were awarded the 2026 Nobel Prize in Chemistry by the Royal Swedish Academy of Sciences in Stockholm, Sweden, on October 7, 2026.

The 2026 Nobel Prize in Physiology or Medicine was awarded to Karl Deisseroth, Peter Hegemann, and Georg Nagel for the development of optogenetics.

Henri B. Kagan and Kenso Soai have been awarded the 2026 Nobel Prize in Chemistry for their breakthroughs in asymmetric organic synthesis.

The ongoing conflict involving Iran is causing significant delays in the delivery of contraceptives to various African clinics.

The European Medicines Agency (EMA) has officially initiated the selection process to appoint its next Executive Director.

The US Food and Drug Administration (FDA) is actively seeking a permanent director for its Office of Therapeutic Products, which oversees cell and gene therapy.

Dr. John Tsai assumed the role of global R&D head at Daiichi Sankyo in 2026.

The U.S. Department of Health and Human Services (HHS) is increasing efforts to accelerate drug development processes.

The U.S. Department of Health and Human Services (HHS) announced $27.8 million in funding for falls prevention initiatives on October 9, 2026.

Astellas Pharma CEO Naoki Okamura presented a new five-year corporate strategic plan in Tokyo in late May 2026.

A 2026 survey by Cardinal Health of 200 biopharma executives reveals that 45% of respondents are considering consolidating their hub vendors by 2028.

Drugmakers Eli Lilly and Novo Nordisk report that GLP-1 weight-loss drugs may slow biological aging based on molecular aging clocks.

The article discusses how Quality Management Maturity (QMM) can assist C-suite executives in identifying supply chain risks, specifically citing a $100 million problem scenario.